Combination fibrate-statin therapy for the treatment of severe hypertriglyceridaemia in renal disease

International Journal of Clinical Practice

Volumn 57, Issue 3, 2003, Pages 249-251

  Badawy, O ^a   Wierzbicki, A S ^a   Hilton, R ^a  

^a ST THOMAS HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALLOPURINOL; AMLODIPINE; ATENOLOL; ATORVASTATIN; BEZAFIBRATE; CERIVASTATIN; CHOLESTEROL; CHYLOMICRON; FENOFIBRATE; FIBRIC ACID DERIVATIVE; FLUINDOSTATIN; FUROSEMIDE; GEMFIBROZIL; HIGH DENSITY LIPOPROTEIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN; MEVINOLIN; OMEPRAZOLE; SIMVASTATIN; TRIACYLGLYCEROL;

ADULT; ARTICLE; CASE REPORT; CHOLESTEROL BLOOD LEVEL; CONTINUOUS AMBULATORY PERITONEAL DIALYSIS; DISEASE SEVERITY; DOSE RESPONSE; DRUG BINDING; DRUG EFFECT; DRUG TOLERABILITY; FEMALE; HUMAN; HYPERTRIGLYCERIDEMIA; KIDNEY FAILURE; MONOTHERAPY; MYALGIA; MYOSITIS; PERITONEAL DIALYSIS; PRIORITY JOURNAL; RHABDOMYOLYSIS; TRIACYLGLYCEROL BLOOD LEVEL;

ANTICHOLESTEREMIC AGENTS; ANTILIPEMIC AGENTS; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERTRIGLYCERIDEMIA; KIDNEY FAILURE, CHRONIC; MIDDLE AGED;

EID: 0037397792     PISSN: 13685031     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (13)

1. Levin A, Djurdjev O, Barrett E et al. Cardiovascular disease in patients with chronic renal disease: getting to the heart of the matter. Am J Kidney Dis 2001; 38: 1398-1407.
2. Weintraub M, Bustein A, Rassin T et al. Severe defect in clearing post-prandial chylomicron remnants in dialysis patients. Kidney Int 1992; 42: 1247-1252.
3. Nestel PJ, Fidge NH, Tan MH. Increased lipoprotein-remnant formation in chronic renal failure. N Engl J Med 1982; 307: 329-333.
4. Lee DM, Knight-Gibson C, Samuelsson O et al. Lipoprotein particle abnormalities and the impaired lipolysis in renal insufficiency. Kidney Int 2002; 61: 209-218.
5. Romero R, Calvino J, Rodriguez J, Sanchez-Guisande D. Short-term effect of atorvastatin in hypercholesterolemic renal-transplant patients unresponsive to other statins. Nephrol Dial Transplant 2000; 15: 1446-1449.
6. Stein EA, Lane M, Laskarzewski P. Comparison of statins in hypertriglyceridaemia. Am J Cardiol 1998; 81: 66B-69B.
7. Wierzbicki AS, Lumb PJ, Chik G, Crook MA. High-density lipoprotein cholesterol and triglyceride response with simvastatin vs atorvastatin in familial hypercholesterolemia. Am J Cardiol 2000; 86: 547-549.
8. Deighan CJ, Caslake MJ, McConnell M et al. Comparative effects of cerivastatin and fenofibrate on the atherogenic lipoprotein phenotype in proteinuric renal disease. J Am Soc Nephrol 2001; 12: 341-348.
9. Vergoulas G, Miserlis G, Soloaki F et al. Combined treatment of hypercholesterolemia of renal transplant allograft recipients with fluvastatin and gemfibrozil. Transpl Int 2000; 13(suppl 1): S64-S67.
10. Wierzbicki AS, Mikhailidis, DP, Wray R et al. Statin-fibrate combination therapy for hyperlipidaemia. Curr Med Res Opin 2003. In press.
11. Kyrlund C, Beckman JT, Kivisto KT et al. Plasma concentrations of active lovastatin acid are markedly increased by gemfibrozil but not by bezafibrate. Clin Pharm Ther 2001; 69: 340-345.
12. Grundy SM. Small LDL, atherogenic dyslipidemia, and the metabolic syndrome. Circulation 1997; 95: 1-4.
13. Wierzbicki AS, Reynolds TM, Crook MA. Usefulness of orlisat in the treatment of severe hypertriglyceridemia. Am J Cardiol 2002; 89: 229-230.